Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the debt to equity ratio high or low?
The debt to equity ratio of -0.12 is 228% below its 5-year average of 0.10, near the low end of its 5-year range (-0.34–3.07).
As of the fiscal period ended Tuesday, June 30, 2026. 127.87% below its 12-month average of 0.44.
Reported quarterly debt to equity ratio; no daily interpolation. Q2 FY2026 (2026-06-30): -0.12.
DEBT TO EQUITY RATIO
-0.12
DEBT TO EQUITY RATIO AVG TTM
0.44
DEBT TO EQUITY RATIO AVG 3Y
0.02
DEBT TO EQUITY RATIO AVG 5Y
0.10
DEBT TO EQUITY RATIO AVG 10Y
0.16
DEBT TO EQUITY RATIO AVG 15Y
N/A
DEBT TO EQUITY RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
-127.87%
CURRENT VS 3Y AVG
-724.41%
CURRENT VS 5Y AVG
-228.11%
CURRENT VS 10Y AVG
-178.17%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
0.14
median of 476 covered companies
CURRENT VS SECTOR MEDIAN
-188.03%
vs the sector median at left
Insight Molecular Diagnostics Inc.
Market Cap
$120.80M
Debt to Equity Ratio
-0.12
TTM Avg
0.44
3Y Avg
0.02
5Y Avg
0.10
Market Cap
$119.09M
Debt to Equity Ratio
0.02
TTM Avg
0.02
3Y Avg
0.02
5Y Avg
0.01
Market Cap
$118.52M
Debt to Equity Ratio
0.27
TTM Avg
0.16
3Y Avg
0.12
5Y Avg
0.10
Market Cap
$122.26M
Debt to Equity Ratio
0.14
TTM Avg
0.14
3Y Avg
0.16
5Y Avg
0.14
Market Cap
$116.59M
Debt to Equity Ratio
0.15
TTM Avg
0.11
3Y Avg
0.12
5Y Avg
0.12
Market Cap
$116.30M
Debt to Equity Ratio
N/A
TTM Avg
230.24
3Y Avg
153.68
5Y Avg
153.68
Market Cap
$115.66M
Debt to Equity Ratio
0.01
TTM Avg
0.00
3Y Avg
0.00
5Y Avg
0.00
Market Cap
$114.76M
Debt to Equity Ratio
0.00
TTM Avg
0.01
3Y Avg
0.01
5Y Avg
0.00
Market Cap
$114.71M
Debt to Equity Ratio
0.00
TTM Avg
0.00
3Y Avg
0.00
5Y Avg
0.00
| NAME | MARKET CAP | DEBT TO EQUITY RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Insight Molecular Diagnostics Inc. (IMDX) | $120.80M | -0.12 | 0.44 | 0.02 | 0.10 |
| TuHURA Biosciences, Inc. (HURA)vs › | $119.09M | 0.02 | 0.02 | 0.02 | 0.01 |
| Caribou Biosciences, Inc. (CRBU)vs › | $118.52M | 0.27 | 0.16 | 0.12 | 0.10 |
| enGene Holdings Inc. (ENGN)vs › | $122.26M | 0.14 | 0.14 | 0.16 | 0.14 |
| Genelux Corporation (GNLX)vs › | $116.59M | 0.15 | 0.11 | 0.12 | 0.12 |
| Foghorn Therapeutics Inc. (FHTX)vs › | $116.30M | N/A | 230.24 | 153.68 | 153.68 |
| Aardvark Therapeutics, Inc. Common Stock (AARD)vs › | $115.66M | 0.01 | 0.00 | 0.00 | 0.00 |
| LENZ Therapeutics, Inc. (LENZ)vs › | $114.76M | 0.00 | 0.01 | 0.01 | 0.00 |
| Coya Therapeutics, Inc. (COYA)vs › | $114.71M | 0.00 | 0.00 | 0.00 | 0.00 |
| Entera Bio Ltd. (ENTX)vs › | $129.39M | 0.06 | 0.04 | 0.03 | 0.03 |
Debt/Equity
-0.12
Current Ratio
2.00
Debt to Equity measures financial leverage by comparing total debt to shareholders' equity.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | DEBT TO EQUITY RATIO |
|---|---|
| 2026-06-30 | -0.12 |
| 2026-03-31 | -0.29 |
| 2025-12-31 | -0.11 |
| 2025-09-30 | -0.34 |
| 2025-06-30 | 3.07 |
| 2025-03-31 | 0.34 |
| 2024-12-31 | -0.30 |
| 2024-09-30 | 0.41 |
| 2024-06-30 | 0.16 |
| 2024-03-31 | 0.20 |
| 2023-12-31 | 0.14 |
| 2023-09-30 | 0.08 |
| 2023-06-30 | 0.06 |
| 2023-03-31 | 0.09 |
| 2022-12-31 | 0.09 |
| 2022-09-30 | 0.05 |
| 2022-06-30 | 0.05 |
| 2022-03-31 | 0.10 |
| 2021-12-31 | 0.09 |
| 2021-09-30 | 0.07 |
| 2021-06-30 | 0.06 |
| 2021-03-31 | 0.08 |
| 2020-12-31 | 0.26 |
| 2020-09-30 | 0.24 |
| 2020-06-30 | 0.19 |
| 2020-03-31 | 0.18 |
| 2019-12-31 | 0.20 |
| 2019-09-30 | 0.05 |
| 2019-06-30 | 0.04 |
| 2019-03-31 | 0.04 |
| 2018-12-31 | 0.50 |
| 2018-09-30 | 0.27 |
| 2018-06-30 | 0.29 |
| 2018-03-31 | 0.25 |
| 2017-12-31 | 0.57 |
| 2017-09-30 | 0.32 |
| 2017-06-30 | 0.52 |
| 2017-03-31 | 0.30 |
| 2016-12-31 | 0.05 |
| 2016-09-30 | 0.03 |
| 2016-06-30 | 0.09 |
| 2016-03-31 | 0.00 |
| 2015-12-31 | 0.00 |
| 2015-09-30 | 0.37 |
| 2015-06-30 | 1.15 |
| 2015-03-31 | 0.00 |
| 2014-12-31 | -5.48 |
| 2014-09-30 | 0.00 |
| 2014-06-30 | 0.00 |
| 2014-03-31 | 0.00 |
